Study: Uterine transplantation is an effective, safe method to remedy infertility

Transplanting a uterus is an effective, safe method to remedy infertility when a functioning uterus is lacking. This is the conclusion from the world's first complete study of uterine transplantation, conducted at the University of Gothenburg.

The study, published in the journal Fertility and Sterility, covers transplantation of uteri from living donors. The operations were headed by Mats Brännström, professor of obstetrics and gynecology at Sahlgrenska Academy, University of Gothenburg, and chief physician at Sahlgrenska University Hospital.

After seven of the study's nine transplants, in vitro fertilization (IVF) treatment ensued. In this group of seven women, six (86%) became pregnant and gave birth. Three had two children each, making the total number of babies nine.

In terms of what is known as the "clinical pregnancy rate as well, the study shows good IVF results. The probability of pregnancy per individual embryo returned to a transplanted uterus was 33%, which is no different from the success rate of IVF treatments overall.

Participants followed up

The researchers note that few cases were studied. Nonetheless, the material -; including extensive, long-term follow-ups of participants' physical and mental health -; is of top world class in the area.

None of the donors had pelvic symptoms but, in a few, the study describes mild, partially transient symptoms in the form of discomfort or minor swelling in the legs.

After four years, health-related quality of life in the recipient group as a whole was higher than in the general population. Neither members of the recipient group nor the donors had levels of anxiety or depression that required treatment.

The children's growth and development were also monitored. The study involves monitoring up to the age of two years and is, accordingly, the longest child follow-up study conducted to date in this context. Further monitoring of these children, up to adulthood, is planned.

Good health in the long term

This is the first complete study that's been done, and the results exceed expectations in terms both of clinical pregnancy rate and of the cumulative live birth rate.

The study also shows positive health outcomes: The children born to date remain healthy and the long-term health of donors and recipients is generally good too."

Mats Brännström, professor of obstetrics and gynecology, Sahlgrenska Academy, University of Gothenburg

The first birth after uterine transplantation took place in Gothenburg in 2014. Another seven births followed, within the framework of the same research project, before anyone outside Sweden gave birth following uterine transplantation.

The research group has since passed on its methods and techniques through direct knowledge transfer to several research centers outside Sweden. By year-end 2021, the number of uterine transplants in the world was estimated at 90, of which 20 had been performed in Sweden. Worldwide, some 50 children have been born after uterine transplantation.

Most of the research groups around the world contribute data on donors, recipients, transplants, births, complications, and other information to the international uterus transplant register, which was initiated and is maintained by the Gothenburg researchers. This register, under the aegis of the International Society of Uterus Transplantation (ISUTx), is expected to be a highly valuable research instrument in the future, serving to make the procedure even safer and more efficacious.

Source:
Journal reference:

Brännström, M., et al. (2022) Reproductive, obstetrical and long-term health outcome after uterus transplantation: results of the first clinical trial. Fertility and Sterility. doi.org/10.1016/j.fertnstert.2022.05.017.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17